Physician profile
Mark Ferretti
NPI 1144621657
$1,996.79
in general payments reported to CMS, 2019-2025
23 companies · $628 in 2025
The $628 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2021: $12.26 · 2022: $70.61 · 2023: $255 · 2024: $821 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $330.28 | 2023-2024 | Zenith Spiral-Z, Zenith |
| Astellas Pharma US INC | $240.06 | 2019-2025 | Xtandi |
| Boston Scientific Corporation | $197.12 | 2022-2025 | Lithovue, Ams 700, Spaceoar System |
| Urogen Pharma, INC. | $159.19 | 2025 | |
| Procept Biorobotics Corporation | $142.49 | 2024 | Aquabeam System |
| Pfizer INC. | $133.50 | 2024-2025 | |
| Teleflex LLC | $130.38 | 2024 | Urolift |
| Coloplast Corp | $112.09 | 2024 | |
| Axonics, INC. | $98.72 | 2023-2024 | Axonics, Bulkamid |
| 180 Medical, INC. | $64.36 | 2024-2025 | |
| Bioprotect Medical, INC. | $58.33 | 2025 | Bioprotect Balloon Implant System |
| Novartis Pharmaceuticals Corporation | $51.43 | 2024-2025 | |
| Janssen Biotech, INC. | $50.53 | 2025 | Erleada |
| Civco Medical Instruments | $38.69 | 2025 | |
| Edap Technomed INC | $36.22 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $34.42 | 2025 | Orgovyx |
| Endo USA, INC. | $28.14 | 2025 | Xiaflex, Aveed |
| Calyxo, INC. | $19.11 | 2025 | Cvac Aspiration System |
| Tolmar, INC. | $16.37 | 2024 | |
| Mimedx Group, INC. | $15.19 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.77 | 2025 | |
| Ferring Pharmaceuticals INC. | $13.14 | 2024 | Adstiladrin |
| Novo Nordisk INC | $12.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ferretti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.